Structure Therapeutics Q2 FY26 net loss widens to $106.16 million; R&D expenses rise to $100.06 million - GPCR News | RalliesStructure Therapeutics Q2 FY26 net loss widens to $106.16 million; R&D expenses rise to $100.06 million
G
GPCR• Cash and investments
- Cash, cash equivalents and short-term investments fell to $1.34 billion as of June 30, 2026, from $1.45 billion at year-end 2025.
Q2 financial results
- Structure Therapeutics posted a Q2 net loss of $106.16 million, widening from $61.66 million a year earlier.
- R&D expense climbed to $100.06 million from $54.71 million; G&A rose to $18.57 million from $15.74 million.
Pipeline progress and upcoming data readouts
- First patients were dosed in the Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 program for aleniglipron in chronic weight management.
- Initial Phase 1 ACCG-2671 SAD data and a MAD trial start are targeted for Q3 2026; ACCESS OLE topline 72-week data are also due in Q3.
•
